[ad_1]
According to the ministry, said call was made in view of the extraordinary epidemiological situation and the circumstances in which surplus vaccines can remain unused after the expiration of the vaccines.
Lithuanian Health Minister Arūnas Dulkys, Latvian Health Minister Danielis Pavlutas and Estonian Health and Labor Minister Tanelis Kiikas sent a joint letter to the European Union Health Commissioner Stela Kiriakides.
“The speech by the three ministers underscores the gratitude of the European Commission and the Commissioner’s team for their continued efforts to increase the production and supply of COVID-19 vaccines from manufacturers. While welcoming the intensive dialogue with manufacturers of vaccines and the more stable, transparent and predictable delivery of vaccines in EU countries, emphasizes the need to assess contingencies when vaccines need to be redistributed between countries urgently, according to the report.
According to the ministers, such decisions should be based on clear and transparent criteria, such as the availability of vaccines, the level of vaccination, the frequency of cases, the mortality rate and the prevalence of new mutations.
The ministers are calling not only for the establishment of a redistribution mechanism in the event of accumulation of unused vaccine surpluses in any Member State, but also for the creation of a special circumstances mechanism that can justify proportional distribution exceptions and temporarily encourage deliveries to those Member States. most needy.
“This would allow EU countries to make more effective use of vaccines produced and distributed at EU level, increase vaccination coverage across the EU and thus help reduce the burden of the pandemic and prevent the spread of the disease. COVID-19 virus, “the report said. .
The European Medicines Agency (EMA) has currently approved COVID-19 vaccines from three manufacturers: Pfizer and BioNTech, Moderna and AstraZeneca.
Its shipments to EU members are distributed in proportion to the population.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
